![European Crohn's and Colitis Organisation returns to Vienna in 2018 - KONGRES – Europe Events and Meetings Industry Magazine European Crohn's and Colitis Organisation returns to Vienna in 2018 - KONGRES – Europe Events and Meetings Industry Magazine](https://kongres-magazine.eu/wp-content/uploads/2017/02/IMG_4737-800x600.jpg)
European Crohn's and Colitis Organisation returns to Vienna in 2018 - KONGRES – Europe Events and Meetings Industry Magazine
![New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn's Disease - European Medical Journal New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn's Disease - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2017/06/PharmaMar-Announces-Encouraging...-940x566.jpg)
New Data Shows Stelara® (Ustekinumab) Maintained Clinical Response and Remission After Two Years of Treatment in Patients with Moderate to Severe Crohn's Disease - European Medical Journal
![Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG‐IBD study - Dragoni - 2023 - United European Gastroenterology Journal - Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG‐IBD study - Dragoni - 2023 - United European Gastroenterology Journal -](https://onlinelibrary.wiley.com/cms/asset/fa34ee68-f9f6-4d4f-ba5c-a3f91b1f5187/ueg212367-toc-0001-m.jpg)
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG‐IBD study - Dragoni - 2023 - United European Gastroenterology Journal -
![Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | Digestive Diseases and Sciences Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | Digestive Diseases and Sciences](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10620-019-06036-0/MediaObjects/10620_2019_6036_Fig1_HTML.png)
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | Digestive Diseases and Sciences
![Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2018/01/New-Website-Photographs-.8-940x564.jpg)
Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal
![Abivax Presents Impressive New Phase 2a ABX464 Ulcerative Colitis 6-Months Maintenance Study Data in Oral Plenary Session at Annual Congress of European Crohn's and Colitis Organisation (ECCO) | Abivax Abivax Presents Impressive New Phase 2a ABX464 Ulcerative Colitis 6-Months Maintenance Study Data in Oral Plenary Session at Annual Congress of European Crohn's and Colitis Organisation (ECCO) | Abivax](https://abivax.gcs-web.com/sites/g/files/knoqqb87736/themes/site/client_site/dist/images/abivax-ir-banner.jpg)